Zynerba Pharmaceuticals Announces Planned Retirement of Suzanne Hanlon and Appoints Albert P. Parker as Chief Legal Officer
February 15 2022 - 7:00AM
Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in
innovative pharmaceutically-produced transdermal cannabinoid
therapies for rare and near-rare neuropsychiatric disorders, today
announced the appointment of Albert P. Parker, an accomplished
industry executive with over 25 years of pharmaceutical, biotech
and healthcare experience, as Chief Legal Officer and Corporate
Secretary. He will assume the duties of Suzanne Hanlon who will
retire from her position at the end of February 2022.
“We are excited to have Al join our senior leadership team. He
is an experienced legal and business executive who brings
significant strategic and hands-on legal and compliance expertise,
coupled with experience developing corporate strategy and
maximizing commercial opportunities at life science companies of
varying sizes,” said Armando Anido, Chairman and Chief Executive
Officer of Zynerba. “I want to personally thank Suzanne for her
significant contributions throughout her eight years at Zynerba as
she successfully developed and led our legal organization and was a
great partner to me, the board of directors and the management
team. While Suzanne’s leadership, experience and friendship will be
missed, I sincerely hope that she enjoys the fruits of a very
successful career in her retirement.”
Mr. Parker served most recently as Chief Operating Officer and
Corporate Secretary of Oncocyte Corporation, an oncology focused
precision diagnostics and monitoring company. Before joining
Oncocyte, Mr. Parker was the Managing Shareholder of GC Legal
Advisors, where he represented and advised public and privately
held companies primarily in the life sciences industry. Among his
prior roles, Mr. Parker has served as Executive Vice President,
General Counsel and Corporate Secretary at Sunovion
Pharmaceuticals, Senior Vice President & Chief Counsel for
Wyeth Pharmaceuticals, and Partner at Schnader Harrison Segal &
Lewis, L.L.P. He earned his Juris Doctorate from the University of
Pennsylvania Carey Law School, and a Bachelor of Arts in Economics
from Penn State University.
About Zynerba Pharmaceuticals, Inc.
Zynerba Pharmaceuticals is the leader in innovative
pharmaceutically-produced transdermal cannabinoid therapies for
rare and near-rare neuropsychiatric disorders. We are committed to
improving the lives of patients and their families living with
severe, chronic health conditions including Fragile X syndrome,
autism spectrum disorder, and 22q11.2 deletion syndrome. Learn more
at www.zynerba.com and follow us on Twitter at
@ZynerbaPharma.
Cautionary Note on Forward-Looking
Statements
This press release contains forward-looking statements within
the meaning of The Private Securities Litigation Reform Act of
1995. We may, in some cases, use terms such as “predicts,”
“believes,” “potential,” “proposed,” “continue,” “estimates,”
“anticipates,” “expects,” “plans,” “intends,” “may,” “could,”
“might,” “will,” “should” or other words that convey uncertainty of
future events or outcomes to identify these forward-looking
statements. Such statements are subject to numerous important
factors, risks and uncertainties that may cause actual events or
results to differ materially from the Company’s current
expectations. Management’s expectations and, therefore, any
forward-looking statements in this press release could also be
affected by risks and uncertainties relating to a number of other
factors, including the following: the Company’s cash and cash
equivalents may not be sufficient to support its operating plan for
as long as anticipated; the Company’s expectations, projections and
estimates regarding expenses, future revenue, capital requirements,
incentive and other tax credit eligibility, collectability and
timing, and availability of and the need for additional financing;
the Company’s ability to obtain additional funding to support its
clinical development programs; the results, cost and timing of the
Company’s clinical development programs, including any delays to
such clinical trials relating to enrollment or site initiation;
clinical results for the Company’s product candidates may not be
replicated or continue to occur in additional trials and may not
otherwise support further development in a specified indication or
at all; actions or advice of the U.S. Food and Drug Administration
and foreign regulatory agencies may affect the design, initiation,
timing, continuation and/or progress of clinical trials or result
in the need for additional clinical trials; the Company’s ability
to obtain and maintain regulatory approval for its product
candidates, and the labeling under any such approval; the Company’s
reliance on third parties to assist in conducting pre-clinical and
clinical trials for its product candidates; delays, interruptions
or failures in the manufacture and supply of the Company’s product
candidates the Company’s ability to commercialize its product
candidates; the size and growth potential of the markets for the
Company’s product candidates, and the Company’s ability to service
those markets; the Company’s ability to develop sales and marketing
capabilities, whether alone or with potential future collaborators;
the rate and degree of market acceptance of the Company’s product
candidates; the Company’s expectations regarding its ability to
obtain and adequately maintain sufficient intellectual property
protection for its product candidates; and the extent to which
health epidemics and other outbreaks of communicable diseases,
including COVID-19, could disrupt our operations or adversely
affect our business and financial conditions. This list is not
exhaustive and these and other risks are described in the Company’s
periodic reports, including the annual report on Form 10-K,
quarterly reports on Form 10-Q and current reports on Form 8-K,
filed with or furnished to the Securities and Exchange Commission
and available at www.sec.gov. Any forward-looking statements
that the Company makes in this press release speak only as of the
date of this press release. The Company assumes no obligation to
update forward-looking statements whether as a result of new
information, future events or otherwise, after the date of this
press release.
Zynerba Contact
Peter VozzoICR WestwickeOffice: 443.213.0505Cell:
443.377.4767Peter.Vozzo@Westwicke.com
Zynerba Pharmaceuticals (NASDAQ:ZYNE)
Historical Stock Chart
From Mar 2024 to Apr 2024
Zynerba Pharmaceuticals (NASDAQ:ZYNE)
Historical Stock Chart
From Apr 2023 to Apr 2024